Histone H3.3-associated chromatin complex (H3.3 complex)

Histone H3.3 is a non-centromeric histone variant that is deposited into chromatin throughout the cell cycle, unlike canonical H3.1/H3.2 which are replication-dependent (UniProt P84243). The H3.3-associated chromatin complexes, primarily involving chaperones such as HIRA (for genic regions) and DAXX/ATRX (for telomeres and heterochromatin), are essential for maintaining genomic stability and regulating transcriptional programs (PubMed 20453818). Mutations in the H3.3 gene or its associated chaperones are frequently identified as oncohistones in pediatric cancers, such as the H3K27M mutation in diffuse intrinsic pontine glioma (DIPG) and H3G34R/V in hemispheric glioblastoma (PubMed 22286061). These mutations lead to a global loss of repressive histone marks like H3K27me3, thereby driving aberrant gene expression and oncogenesis. Therapeutic targeting of these complexes involves the use of HDAC inhibitors, EZH2 inhibitors, or novel compounds like ONC201 that exploit the unique vulnerabilities of H3.3-mutant cells (PubMed 30622179). Because these complexes are central to epigenetic regulation, they represent a critical node for intervention in high-grade pediatric malignancies where traditional chemotherapy often fails.

Other names

H3F3AH3F3BH3.3-DAXX-ATRX complexH3.3-HIRA complexHistone H3.3 chaperone complex

Epigenetic reprogramming through HDAC inhibition, ClpP activation leading to mitochondrial stress, or competitive inhibition of histone methyltransferases.